Meeting
2023 ASCO Annual Meeting
Tazemetostat, a selective EZH2 inhibitor, with pembrolizumab as treatment of anti-PD-1 resistant head and neck squamous-cell carcinoma (HNSCC): A phase 1-2 trial.
Authors
Sidharth Puram
Washington University School of Medicine, St. Louis, MO
Sidharth Puram , Peter John Oppelt , Jessica C. Ley , Jared Cohen , Justin Alberti , Erik Shannon , Jingxia Liu , Douglas Adkins
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04624113
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6022)
DOI
10.1200/JCO.2023.41.16_suppl.6022
Abstract #
6022
Poster Bd #
14
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1.
First Author: Bernard Doger de Spéville
Poster
2017 ASCO Annual Meeting
Phase I study of the anti-HGF monoclonal antibody (mAb), ficlatuzumab, and cetuximab in cetuximab-resistant, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
First Author: Julie E. Bauman
Poster
2024 ASCO Annual Meeting
A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183).
First Author: Maha H. A. Hussain
Poster
2023 ASCO Annual Meeting
A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer.
First Author: Christine H. Chung